Carfilzomib or bortezomib in combination with lenalidomide and dexamethasone for patients with newly diagnosed multiple myeloma without intention for immediate autologous stem-cell transplantation (ENDURANCE): a multicentre, open-label, phase 3, randomised, controlled trial
Shaji Kumar(Mayo Clinic in Arizona), Susanna Jacobus(Dana-Farber Cancer Institute), Adam D. Cohen(University of Pennsylvania), Matthias Weiss(ThedaCare), Natalie S. Callander(University of Wisconsin–Madison), Avina K. Singh(Minnesota Oncology), Terri L. Parker(Yale University), Alexander Menter(Kaiser Permanente Lone Tree Medical Offices), Xuezhong Yang(OSF Saint Francis Medical Center), Benjamin M. Parsons(Gundersen Health System), Pankaj Kumar(Illinois CancerCare), Prashant Kapoor(Mayo Clinic in Arizona), Aaron S. Rosenberg(UC Davis Comprehensive Cancer Center), Jeffrey A. Zonder(The Barbara Ann Karmanos Cancer Institute), Edward A. Faber(Oncology Hematology Care), Sagar Lonial(Emory University), Kenneth C. Anderson(Dana-Farber Cancer Institute), Paul G. Richardson(Dana-Farber Cancer Institute), Robert Z. Orlowski(The University of Texas MD Anderson Cancer Center), Lynne I. Wagner(Wake Forest University), S. Vincent Rajkumar(Mayo Clinic in Arizona)
Cited by 251Open Access
Abstract
Related Papers
No related papers found
Powered by citation graph analysis